On the public citation graph

https://doi.org/10.2139/ssrn.4626540

0 signed · 33 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/anie.201204631openalex-extracted
Small Targeted Cytotoxics: Current State and Promises from DNA‐Encoded Chemical Libraries
inferredcites →https://doi.org/10.1002/anie.201310709openalex-extracted
A Small‐Molecule Drug Conjugate for the Treatment of Carbonic Anhydrase IX Expressing Tumors
inferredcites →https://doi.org/10.1002/jcp.27085openalex-extracted
Trastuzumab‐monomethyl auristatin E conjugate exhibits potent cytotoxic activity in vitro against HER2‐positive human breast cancer
inferredcites →https://doi.org/10.1002/pros.20753openalex-extracted
Cell‐Surface labeling and internalization by a fluorescent inhibitor of prostate‐specific membrane antigen
inferredcites →https://doi.org/10.1007/978-1-4939-9929-3openalex-extracted
Antibody-Drug Conjugates
inferredcites →https://doi.org/10.1007/s11095-015-1729-8openalex-extracted
Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates
inferredcites →https://doi.org/10.1007/s40265-017-0705-5openalex-extracted
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma
inferredcites →https://doi.org/10.1016/j.addr.2007.06.008openalex-extracted
Endocytic mechanisms for targeted drug delivery☆
inferredcites →https://doi.org/10.1016/j.bmc.2004.06.031openalex-extracted
Probing for a hydrophobic a binding register in prostate-specific membrane antigen with phenylalkylphosphonamidates
inferredcites →https://doi.org/10.1016/j.bmc.2007.07.028openalex-extracted
The molecular pruning of a phosphoramidate peptidomimetic inhibitor of prostate-specific membrane antigen
inferredcites →https://doi.org/10.1016/j.bmcl.2010.09.057openalex-extracted
A targeted low molecular weight near-infrared fluorescent probe for prostate cancer
inferredcites →https://doi.org/10.1016/j.bmcl.2019.08.005openalex-extracted
Phosphoramidate derivates as controlled-release prodrugs of l-Dopa
inferredcites →https://doi.org/10.1016/j.ejmech.2018.12.035openalex-extracted
Small molecule-drug conjugates: A novel strategy for cancer-targeted treatment
inferredcites →https://doi.org/10.1016/j.tetlet.2020.152398openalex-extracted
A click-ready pH-triggered phosphoramidate-based linker for controlled release of monomethyl auristatin E
inferredcites →https://doi.org/10.1021/acs.bioconjchem.1c00435openalex-extracted
Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b00457openalex-extracted
Antibody–Drug Conjugates and Small Molecule–Drug Conjugates: Opportunities and Challenges for the Development of Selective Anticancer Cytotoxic Agents
inferredcites →https://doi.org/10.1021/acs.jmedchem.5b01850openalex-extracted
Structure–Activity Relationship of 18F-Labeled Phosphoramidate Peptidomimetic Prostate-Specific Membrane Antigen (PSMA)-Targeted Inhibitor Analogues for PET Imaging of Prostate Cancer
inferredcites →https://doi.org/10.1021/bc2005522openalex-extracted
Engineering Folate–Drug Conjugates to Target Cancer: From Chemistry to Clinic
inferredcites →https://doi.org/10.1021/bi801883vopenalex-extracted
Pseudoirreversible Inhibition of Prostate-Specific Membrane Antigen by Phosphoramidate Peptidomimetics
inferredcites →https://doi.org/10.1038/nbt832openalex-extracted
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
inferredcites →https://doi.org/10.1038/nrd.2016.268openalex-extracted
Strategies and challenges for the next generation of antibody–drug conjugates
inferredcites →https://doi.org/10.1039/c8cs00676hopenalex-extracted
Cleavable linkers in antibody–drug conjugates
inferredcites →https://doi.org/10.1039/d0nj04134copenalex-extracted
Small molecule drug conjugates (SMDCs): an emerging strategy for anticancer drug design and discovery
inferredcites →https://doi.org/10.1158/1535-7163.mct-22-0160openalex-extracted
Modular Smart Molecules for PSMA-Targeted Chemotherapy
inferredcites →https://doi.org/10.1186/s13046-017-0667-1openalex-extracted
Fate of Antibody-Drug Conjugates in Cancer Cells
inferredcites →https://doi.org/10.1248/cpb.c19-00853openalex-extracted
Antibody–Drug Conjugate Payloads; Study of Auristatin Derivatives
inferredcites →https://doi.org/10.1593/neo.04349openalex-extracted
Bone Microenvironment Modulates Expression and Activity of Cathepsin B in Prostate Cancer
inferredcites →https://doi.org/10.2174/138945012802429615openalex-extracted
Overcoming Drug Resistance and Treating Advanced Prostate Cancer
inferredcites →https://doi.org/10.2967/jnumed.117.203877openalex-extracted
A Perspective on the Evolving Story of PSMA Biology, PSMA-Based Imaging, and Endoradiotherapeutic Strategies
inferredcites →https://doi.org/10.3390/cancers13040779openalex-extracted
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
inferredcites →https://doi.org/10.3390/jcm10061323openalex-extracted
Preclinical Characterization of the Distribution, Catabolism, and Elimination of a Polatuzumab Vedotin-Piiq (POLIVY®) Antibody–Drug Conjugate in Sprague Dawley Rats
inferredcites →https://doi.org/10.3892/ijo_00000553openalex-extracted
Targeted photodynamic therapy for prostate cancer: Inducing apoptosis via activation of the caspase-8/-3 cascade pathway
inferredcites →https://doi.org/10.7150/thno.18719openalex-extracted
177Lu-Labeled Phosphoramidate-Based PSMA Inhibitors: The Effect of an Albumin Binder on Biodistribution and Therapeutic Efficacy in Prostate Tumor-Bearing Mice
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.